CoChat
Sign Up
Cited by 8Burkholderia infections and melioidosisBacterial Infections and VaccinesInfections and bacterial resistance

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Burkholderia pseudomallei Complex Subunit and Glycoconjugate Vaccines and Their Potential to Elicit Cross-Protection to Burkholderia cepacia Complex

Open access
Badten, Alexander J., Torres, Alfredo G.·2024·Vaccines
DOI 10.3390/vaccines12030313PMC PMC10975474

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Burkholderia are a group of Gram-negative bacteria that can cause a variety of diseases in at-risk populations. B. pseudomallei and B. mallei, the etiological agents of melioidosis and glanders, respectively, are the two clinically relevant members of the B. pseudomallei complex (Bpc). The development of vaccines against Bpc species has been accelerated in recent years, resulting in numerous promising subunits and glycoconjugate vaccines incorporating a variety of antigens. However, a second group of pathogenic Burkholderia species exists known as the Burkholderia cepacia complex (Bcc), a group of opportunistic bacteria which tend to affect individuals with weakened immunity or cystic fibrosis. To date, there have been few attempts to develop vaccines to Bcc species. Therefore, the primary goal of this review is to provide a broad overview of the various subunit antigens that have been tested in Bpc species, their protective efficacy, study limitations, and known or suspected mechanisms of protection. Then, we assess the reviewed Bpc antigens for their amino acid sequence conservation to homologous proteins found in Bcc species. We propose that protective Bpc antigens with a high degree of Bpc-to-Bcc sequence conservation could serve as components of a pan-Burkholderia vaccine capable of protecting against both disease-causing groups.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/vaccines12030313

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 248

  1. Elshafie, H.S., and Camele, I. (2021). An Overview of Metabolic Activity, Beneficial and Pathogenic Aspects of Burkholderia spp.. Metabolites, 11. · DOI
  2. Eberl, 2016, Members of the genus Burkholderia: Good and bad guys, F1000Research, 5, F1000 Faculty Rev-1007, 10.12688/f1000research.8221.1 · DOI
  3. Parte, 2020, List of Prokaryotic names with Standing in Nomenclature (LPSN) moves to the DSMZ, Int. J. Syst. Evol. Microbiol., 70, 5607, 10.1099/ijsem.0.004332 · DOI
  4. Limmathurotsakul, D., Golding, N., Dance, D.A.B., Messina, J.P., Pigott, D.M., Moyes, C.L., Rolim, D.B., Bertherat, E., Day, N.P.J., and Peacock, S.J. (2016). Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat. Microbiol., 1. · DOI
  5. Zlosnik, 2011, Mucoid and Nonmucoid Burkholderia cepacia Complex Bacteria in Cystic Fibrosis Infections, Am. J. Respir. Crit. Care Med., 183, 67, 10.1164/rccm.201002-0203OC · DOI
  6. Folescu, T.W., da Costa, C.H., Cohen, R.W.F., Cohen, R., da Conceição Neto, O.C., Albano, R.M., and Marques, E.A. (2015). Burkholderia cepacia complex: Clinical course in cystic fibrosis patients. BMC Pulm. Med., 15. · DOI
  7. Atkinson, 2020, Systematic review of healthcare-associated Burkholderia cepacia complex outbreaks: Presentation, causes and outbreak control, Infect. Prev. Pract., 2, 100082, 10.1016/j.infpip.2020.100082 · DOI
  8. Pongmala, 2022, Distribution of Burkholderia pseudomallei within a 300-cm deep soil profile: Implications for environmental sampling, Sci. Rep., 12, 8674, 10.1038/s41598-022-12795-0 · DOI
  9. Merritt, 2017, The Role of Climate in the Epidemiology of Melioidosis, Curr. Trop. Med. Rep., 4, 185, 10.1007/s40475-017-0124-4 · DOI
  10. Chai, 2018, Earth, wind, rain, and melioidosis, Lancet Planet Health, 2, E329, 10.1016/S2542-5196(18)30165-7 · DOI
  11. Birnie, 2022, Drivers of melioidosis endemicity: Epidemiological transition, zoonosis, and climate change, Curr. Opin. Infect. Dis., 35, 196, 10.1097/QCO.0000000000000827 · DOI
  12. Gassiep, 2023, Expanding the Geographic Boundaries of Melioidosis in Queensland, Australia, Am. J. Trop. Med. Hyg., 108, 1215, 10.4269/ajtmh.23-0002 · DOI
  13. Wiersinga, 2018, Melioidosis, Nat. Rev. Dis. Primers, 4, 17107, 10.1038/nrdp.2017.107 · DOI
  14. Singh, 2017, Melioidosis: The great mimicker, J. Community Hosp. Intern. Med. Perspect., 7, 245, 10.1080/20009666.2017.1348875 · DOI
  15. Khakhum, 2020, Combating the great mimicker: Latest progress in the development of Burkholderia pseudomallei vaccines, Expert Rev. Vaccines, 19, 653, 10.1080/14760584.2020.1791089 · DOI
  16. Losada, 2010, Continuing Evolution of Burkholderia mallei through Genome Reduction and Large-Scale Rearrangements, Genome Biol. Evol., 2, 102, 10.1093/gbe/evq003 · DOI
  17. Nielsen, 2022, Assessment of the control measures of the category A diseases of Animal Health Law: Burkholderia mallei (Glanders), EFSA J., 20, e07069
  18. Greer, 2013, Glanders: An overview of infection in humans, Orphanet J. Rare Dis., 8, 131, 10.1186/1750-1172-8-131 · DOI
  19. Godoy, 2003, Multilocus Sequence Typing and Evolutionary Relationships among the Causative Agents of Melioidosis and Glanders, Burkholderia pseudomallei and Burkholderia mallei, J. Clin. Microbiol., 41, 2068, 10.1128/JCM.41.5.2068-2079.2003 · DOI
  20. Bzdyl, 2022, Pathogenicity and virulence of Burkholderia pseudomallei, Virulence, 13, 1945, 10.1080/21505594.2022.2139063 · DOI
  21. Lavelle, 2022, Mucosal vaccines—Fortifying the frontiers, Nat. Rev. Immunol., 22, 236, 10.1038/s41577-021-00583-2 · DOI
  22. Ho, 1997, Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies, Infect. Immun., 65, 3648, 10.1128/iai.65.9.3648-3653.1997 · DOI
  23. Su, 2010, Immunization with the recombinant Burkholderia pseudomallei outer membrane protein Omp85 induces protective immunity in mice, Vaccine, 28, 5005, 10.1016/j.vaccine.2010.05.022 · DOI
  24. Zhang, 2011, In Vitro and In Vivo Studies of Monoclonal Antibodies with Prominent Bactericidal Activity against Burkholderia pseudomallei and Burkholderia mallei, Clin. Vaccine Immunol., 18, 825, 10.1128/CVI.00533-10 · DOI
  25. Burtnick, M.N., Heiss, C., Schuler, A.M., Azadi, P., and Brett, P.J. (2012). Development of novel O-polysaccharide based glycoconjugates for immunization against glanders. Front. Cell. Infect. Microbiol., 2. · DOI
  26. Gourlay, 2013, Exploiting the Burkholderia pseudomallei Acute Phase Antigen BPSL2765 for Structure-Based Epitope Discovery/Design in Structural Vaccinology, Chem. Biol., 20, 1147, 10.1016/j.chembiol.2013.07.010 · DOI
  27. Burtnick, 2018, Development of Subunit Vaccines That Provide High-Level Protection and Sterilizing Immunity against Acute Inhalational Melioidosis, Infect. Immun., 86, e00724-17, 10.1128/IAI.00724-17 · DOI
  28. Schmidt, 2022, Development of Melioidosis Subunit Vaccines Using an Enzymatically Inactive Burkholderia pseudomallei AhpC, Infect. Immun., 90, e00222-22, 10.1128/iai.00222-22 · DOI
  29. Jenjaroen, K., Chumseng, S., Sumonwiriya, M., Ariyaprasert, P., Chantratita, N., Sunyakumthorn, P., Hongsuwan, M., Wuthiekanun, V., Fletcher, H.A., and Teparrukkul, P. (2015). T-Cell Responses Are Associated with Survival in Acute Melioidosis Patients. PLoS Negl. Trop. Dis., 9. · DOI
  30. Kronsteiner, 2019, Diabetes alters immune response patterns to acute melioidosis in humans, Eur. J. Immunol., 49, 1092, 10.1002/eji.201848037 · DOI
  31. Morales-Ruíz, L.M., Rodríguez-Cisneros, M., Kerber-Díaz, J.C., Rojas-Rojas, F.U., Ibarra, J.A., and Los Santos, P.E. (2022). Burkholderia orbicola sp. nov., a novel species within the Burkholderia cepacia complex. Arch. Microbiol., 204. · DOI
  32. Tavares, 2020, Burkholderia cepacia Complex Bacteria: A Feared Contamination Risk in Water-Based Pharmaceutical Products, Clin. Microbiol. Rev., 33, e00139-19, 10.1128/CMR.00139-19 · DOI
  33. Alicandro, 2023, Cepacia syndrome in cystic fibrosis: A systematic review of the literature and possible new perspectives in treatment, Pediatr. Pulmonol., 58, 1337, 10.1002/ppul.26359 · DOI
  34. Mahenthiralingam, 2005, The multifarious, multireplicon Burkholderia cepacia complex, Nat. Rev. Microbiol., 3, 144, 10.1038/nrmicro1085 · DOI
  35. Horsley, A., Webb, K., Bright-Thomas, R., Govan, J., and Jones, A. (2011). Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy?. Front. Cell. Infect. Microbiol., 1. · DOI
  36. Lord, 2020, Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation, Cochrane Database Sys. Rev., 2020, CD009529
  37. LiPuma, 2010, The Changing Microbial Epidemiology in Cystic Fibrosis, Clin. Microbiol. Rev., 23, 299, 10.1128/CMR.00068-09 · DOI
  38. Zlosnik, 2020, Epidemiology of Burkholderia Infections in People with Cystic Fibrosis in Canada between 2000 and 2017, Ann. Am. Thorac. Soc., 17, 1549, 10.1513/AnnalsATS.201906-443OC · DOI
  39. Pradenas, G.A., Ross, B.N., and Torres, A.G. (2016). Burkholderia cepacia Complex Vaccines: Where Do We Go from here?. Vaccines, 4. · DOI
  40. Grund, M.E., Soo, J.C., Cote, C.K., Berisio, R., and Lukomski, S. (2021). Thinking Outside the Bug: Targeting Outer Membrane Proteins for Burkholderia Vaccines. Cells, 10. · DOI
  41. Irudal, S., Scoffone, V.C., Trespidi, G., Barbieri, G., D’Amato, M., Viglio, S., Pizza, M., Scarselli, M., Riccardi, G., and Buroni, S. (2023). Identification by Reverse Vaccinology of Three Virulence Factors in Burkholderia cenocepacia That May Represent Ideal Vaccine Antigens. Vaccines, 11. · DOI
  42. Cocorullo, M., Chiarelli, L.R., and Stelitano, G. (2023). Improving Protection to Prevent Bacterial Infections: Preliminary Applications of Reverse Vaccinology against the Main Cystic Fibrosis Pathogens. Vaccines, 11. · DOI
  43. Luangasanatip, N., Flasche, S., Dance, D.A.B., Limmathurotsakul, D., Currie, B.J., Mukhopadhyay, C., Atkins, T., Titball, R., and Jit, M. (2019). The global impact and cost-effectiveness of a melioidosis vaccine. BMC Med., 17. · DOI
  44. Altschul, 1990, Basic local alignment search tool, J. Mol. Biol., 215, 403, 10.1016/S0022-2836(05)80360-2 · DOI · Paper page
  45. Altschul, 1997, Gapped BLAST and PSI-BLAST: A new generation of protein database search programs, Nucleic Acids Res., 25, 3389, 10.1093/nar/25.17.3389 · DOI · Paper page
  46. Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., and Madden, T.L. (2008). BLAST+: Architecture and applications. BMC Bioinform., 10. · DOI · Paper page
  47. Scholz, 2006, Detection of the reemerging agent Burkholderia mallei in a recent outbreak of glanders in the United Arab Emirates by a newly developed fliP-based polymerase chain reaction assay, Diag. Microbiol. Infect. Dis., 54, 241, 10.1016/j.diagmicrobio.2005.09.018 · DOI
  48. Chua, 2003, Flagella Are Virulence Determinants of Burkholderia pseudomallei, Infect. Immun., 71, 1622, 10.1128/IAI.71.4.1622-1629.2003 · DOI
  49. Chuaygud, 2008, A role of Burkholderia pseudomallei flagella as a virulent factor, Trans. R. Soc. Trop. Med. Hyg., 102, S140, 10.1016/S0035-9203(08)70031-2 · DOI
  50. Tomich, 2002, Role of Flagella in Host Cell Invasion by Burkholderia cepacia, Infect Immun, 70, 1799, 10.1128/IAI.70.4.1799-1806.2002 · DOI
  51. Urban, 2004, Contribution of Burkholderia cenocepacia Flagella to Infectivity and Inflammation, Infect. Immun., 72, 5126, 10.1128/IAI.72.9.5126-5134.2004 · DOI
  52. Ceballos-Olvera, I., Sahoo, M., Miller, M.A., del Barria, L., and Re, F. (2011). Inflammasome-dependent Pyroptosis and IL-18 Protect against Burkholderia pseudomallei Lung Infection while IL-1β Is Deleterious. PLoS Pathog., 7. · DOI
  53. West, T.E., Myers, N.D., Chantratita, N., Chierakul, W., Limmathurotsakul, D., Wuthiekanun, V., Miao, E.A., Hajjar, A.M., Peacock, S.J., and Liggitt, H.D. (2014). NLRC4 and TLR5 Each Contribute to Host Defense in Respiratory Melioidosis. PLoS Negl. Trop. Dis., 8. · DOI
  54. Koosakulnirand, S., Phokrai, P., Jenjaroen, K., Roberts, R.A., Utaisincharoen, P., Dunachie, S.J., Brett, P.J., Burtnick, M.N., and Chantratita, N. (2018). Immune response to recombinant Burkholderia pseudomallei FliC. PLoS ONE, 13. · DOI
  55. Amemiya, K., Dankmeyer, J.L., Bernhards, R.C., Fetterer, D.P., Waag, D.M., Worsham, P.L., and DeShazer, D. (2021). Activation of Toll-Like Receptors by Live Gram-Negative Bacterial Pathogens Reveals Mitigation of TLR4 Responses and Activation of TLR5 by Flagella. Front. Cell. Infect. Microbiol., 11. · DOI
  56. Nakamura, S., and Minamino, T. (2019). Flagella-Driven Motility of Bacteria. Biomolecules, 9. · DOI
  57. Brett, 1994, Isolation and characterization of Pseudomonas pseudomallei flagellin proteins, Infect. Immun., 62, 1914, 10.1128/iai.62.5.1914-1919.1994 · DOI
  58. Brett, 1996, Structural and Immunological Characterization of Burkholderia pseudomallei O-Polysaccharide–Flagellin Protein Conjugates, Infect. Immun., 64, 2824, 10.1128/iai.64.7.2824-2828.1996 · DOI
  59. Chen, 2006, Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellin, Vaccine, 24, 750, 10.1016/j.vaccine.2005.08.069 · DOI
  60. Chen, 2006, CpG-Modified Plasmid DNA Encoding Flagellin Improves Immunogenicity and Provides Protection against Burkholderia pseudomallei Infection in BALB/c Mice, Infect. Immun., 74, 1699, 10.1128/IAI.74.3.1699-1705.2006 · DOI
  61. Torres, 2015, Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine, Vaccine, 33, 686, 10.1016/j.vaccine.2014.11.057 · DOI
  62. Gregory, 2015, A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei, Nanomedicine, 11, 447, 10.1016/j.nano.2014.08.005 · DOI
  63. Muruato, 2017, Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei, Clin. Vaccine Immunol., 24, e00206-17, 10.1128/CVI.00206-17 · DOI
  64. Tapia, 2020, Multicomponent gold nano-glycoconjugate as a highly immunogenic and protective platform against Burkholderia mallei, Npj Vaccines, 5, 82, 10.1038/s41541-020-00229-9 · DOI
  65. Tapia, 2021, Multicomponent Gold-Linked Glycoconjugate Vaccine Elicits Antigen-Specific Humoral and Mixed TH1-TH17 Immunity, Correlated with Increased Protection against Burkholderia pseudomallei, mBio, 12, e01227-21, 10.1128/mBio.01227-21 · DOI
  66. Hajam, 2017, Bacterial flagellin—A potent immunomodulatory agent, Exp. Mol. Med., 49, e373, 10.1038/emm.2017.172 · DOI
  67. Charuchaimontri, 1999, Antilipopolysaccharide II: An antibody protective against fatal melioidosis, Clin. Infect. Dis., 29, 813, 10.1086/520441 · DOI
  68. Chen, 2003, Recombinant Truncated Flagellin of Burkholderia pseudomallei as a Molecular Probe for Diagnosis of Melioidosis, Clin. Diagn. Lab. Immunol., 10, 423
  69. Felgner, 2009, A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens, Proc. Natl. Acad. Sci. USA, 106, 13499, 10.1073/pnas.0812080106 · DOI
  70. Suwannasaen, 2011, Human Immune Responses to Burkholderia pseudomallei Characterized by Protein Microarray Analysis, J. Infect. Dis., 203, 1002, 10.1093/infdis/jiq142 · DOI
  71. Kohler, C., Dunachie, S.J., Müller, E., Kohler, A., Jenjaroen, K., Teparrukkul, P., Baier, V., Ehricht, R., and Steinmetz, I. (2016). Rapid and Sensitive Multiplex Detection of Burkholderia pseudomallei-Specific Antibodies in Melioidosis Patients Based on a Protein Microarray Approach. PLoS Negl. Trop. Dis., 10. · DOI
  72. Scott, 2011, Flagellar Glycosylation in Burkholderia pseudomallei and Burkholderia thailandensis, J. Bacteriol., 193, 3577, 10.1128/JB.01385-10 · DOI
  73. Hanuszkiewicz, 2014, Identification of the Flagellin Glycosylation System in Burkholderia cenocepacia and the Contribution of Glycosylated Flagellin to Evasion of Human Innate Immune Responses, J. Biol. Chem., 289, 19231, 10.1074/jbc.M114.562603 · DOI
  74. DeShazer, 1997, Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: Isolation of Motility Mutants and Molecular Characterization of the Flagellin Structural Gene, J. Bacteriol., 179, 2116, 10.1128/jb.179.7.2116-2125.1997 · DOI
  75. Wikraiphat, 2009, Comparative in vivo and in vitro analyses of putative virulence factors of Burkholderia pseudomallei using lipopolysaccharide, capsule and flagellin mutants, FEMS Immunol. Med. Microbiol., 56, 253, 10.1111/j.1574-695X.2009.00574.x · DOI
  76. Whitlock, 2010, Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge, Procedia Vaccinol., 2, 73, 10.1016/j.provac.2010.03.013 · DOI
  77. Hales, 1998, Variation in Flagellin Genes and Proteins of Burkholderia cepacia, J. Bacteriol., 180, 1110, 10.1128/JB.180.5.1110-1118.1998 · DOI
  78. Musson, 2014, CD4+ T Cell Epitopes of FliC Conserved between Strains of Burkholderia: Implications for Vaccines against Melioidosis and Cepacia Complex in Cystic Fibrosis, J. Immunol., 193, 6041, 10.4049/jimmunol.1402273 · DOI
  79. Deng, 2017, Assembly, structure, function and regulation of type III secretion systems, Nat. Rev. Microbiol., 15, 323, 10.1038/nrmicro.2017.20 · DOI
  80. Wagner, S., Grin, I., Malmsheimer, S., Singh, N., Torres-Vargas, C.E., and Westerhausen, S. (2018). Bacterial type III secretion systems: A complex device for the delivery of bacterial effector proteins into eukaryotic host cells. FEMS Microbiol. Lett., 365. · DOI
  81. Goodin, 2005, Yersinia pestis outer membrane type III secretion protein YscC: Expression, purification, characterization, and induction of specific antiserum, Protein Expr. Purif., 40, 152, 10.1016/j.pep.2004.11.001 · DOI
  82. Fasciano, A.C., Shaban, L., and Mecsas, J. (2019). Promises and Challenges of the Type Three Secretion System-Injectisome as an Anti-Virulence Target. EcoSal Plus, 8. · DOI
  83. Hotinger, J.A., and May, A.E. (2020). Antibodies Inhibiting the Type III Secretion System of Gram-Negative Pathogenic Bacteria. Antibodies, 9. · DOI
  84. Hotinger, J.A., Pendergrass, H.A., and May, A.E. (2021). Molecular Targets and Strategies for Inhibition of the Bacterial Type III Secretion System (T3SS); Inhibitors Directly Binding to T3SS Components. Biomolecules, 11. · DOI
  85. Wallner, A., Moulin, L., Busset, N., Rimbault, I., and Béna, G. (2021). Genetic Diversity of Type 3 Secretion System in Burkholderia s.l. and Links with Plant Host Adaptation. Front. Microbiol., 12. · DOI
  86. Rainbow, 2002, Distribution of type III secretion gene clusters in Burkholderia pseudomallei, B. thailandensis and B. mallei, J. Med. Microbiol., 51, 374, 10.1099/0022-1317-51-5-374 · DOI
  87. Vander Broek, C.W., and Stevens, J.M. (2017). Type III Secretion in the Melioidosis Pathogen Burkholderia pseudomallei. Front. Cell. Infect. Microbiol., 7. · DOI
  88. Stevens, 2002, An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen, Mol. Microbiol., 46, 649, 10.1046/j.1365-2958.2002.03190.x · DOI
  89. Gutierrez, M.G., Pfeffer, T.L., and Warawa, J.M. (2015). Type 3 Secretion System Cluster 3 Is a Critical Virulence Determinant for Lung-Specific Melioidosis. PLoS Negl. Trop. Dis., 9. · DOI
  90. Kurtz, 2014, Vaccination with a Single CD4 T Cell Peptide Epitope from a Salmonella Type III-Secreted Effector Protein Provides Protection against Lethal Infection, Infect. Immun., 82, 2424, 10.1128/IAI.00052-14 · DOI
  91. Lee, 2017, Dual immunization with SseB/flagellin provides enhanced protection against Salmonella infection mediated by circulating memory cells, J. Immunol., 199, 1353, 10.4049/jimmunol.1601357 · DOI
  92. Xiong, 2017, Identification of Coxiella burnetii CD8+ T-Cell Epitopes and Delivery by Attenuated Listeria monocytogenes as a Vaccine Vector in a C57BL/6 Mouse Model, J. Infect. Dis., 215, 1580
  93. Harley, 1998, An ultrastructural study of the phagocytosis of Burkholderia pseudomallei, Microbios, 94, 35
  94. 2008, The Salmonella-containing Vacuole—Moving with the Times, Curr. Opin. Microbiol., 11, 38, 10.1016/j.mib.2008.01.002 · DOI
  95. Allwood, E.M., Devenish, R.J., Prescott, M., Adler, B., and Boyce, J.D. (2011). Strategies for Intracellular Survival of Burkholderia pseudomallei. Front. Microbiol., 2. · DOI
  96. Latomanski, 2018, Interaction between autophagic vesicles and the Coxiella-containing vacuole requires CLTC (clathrin heavy chain), Autophagy, 14, 1710, 10.1080/15548627.2018.1483806 · DOI
  97. Stevens, 2004, Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis, Microbiology, 150, 2669, 10.1099/mic.0.27146-0 · DOI
  98. Druar, 2007, Evaluating Burkholderia pseudomallei Bip proteins as vaccines and Bip antibodies as detection agents, FEMS Microbiol. Immunol., 52, 78, 10.1111/j.1574-695X.2007.00345.x · DOI
  99. Pumirat, P., Cuccui, J., Stabler, R.A., Stevens, J.M., Muangsombut, V., Singsuksawat, E., Stevens, M.P., Wren, B.W., and Korbsrisate, S. (2010). Global transcriptional profiling of Burkholderia pseudomallei under salt stress reveals differential effects on the Bsa type III secretion system. BMC Microbiol., 10. · DOI
  100. Ooi, W.F., Ong, C., Nandi, T., Kreisberg, J.F., Chua, H.H., Sun, G., Chen, Y., Mueller, C., Conejero, L., and Eshaghi, M. (2013). The Condition-Dependent Transcriptional Landscape of Burkholderia pseudomallei. PLoS Genet., 9. · DOI
  101. Kong, 2023, Transcriptional landscape of Burkholderia pseudomallei cultured under environmental and clinical conditions, Microb. Genom., 9, mgen000982
  102. Leyton, 2012, From self sufficiency to dependence: Mechanisms and factors important for autotransporter biogenesis, Nat. Rev. Microbiol., 10, 213, 10.1038/nrmicro2733 · DOI
  103. Clarke, 2022, Phylogenetic Classification and Functional Review of Autotransporters, Front. Immunol., 13, 921272, 10.3389/fimmu.2022.921272 · DOI
  104. Adler, N.R.L., Stevens, J.M., Stevens, M.P., and Galyov, E.E. (2011). Autotransporters and Their Role in the Virulence of Burkholderia pseudomallei and Burkholderia mallei. Front. Microbiol., 2. · DOI
  105. Stevens, 2005, Identification of a bacterial factor required for actin-based motility of Burkholderia pseudomallei, Mol. Microbiol., 56, 40, 10.1111/j.1365-2958.2004.04528.x · DOI
  106. Campos, 2013, Characterization of BcaA, a putative classical autotransporter protein in Burkholderia pseudomallei, Infect. Immun., 81, 1121, 10.1128/IAI.01453-12 · DOI
  107. Zimmerman, 2017, Antibodies against In Vivo-Expressed Antigens Are Sufficient to Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei, Infect. Immun., 85, e00102-17, 10.1128/IAI.00102-17 · DOI
  108. Mil-Homens, D., and Fialho, A.M. (2011). Trimeric autotransporter adhesins in members of the Burkholderia cepacia complex: A multifunctional family of proteins implicated in virulence. Front. Cell. Infect. Microbiol., 1. · DOI
  109. Lafontaine, 2019, The autotransporter protein BatA is a protective antigen against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei, Vaccine X, 1, 100002, 10.1016/j.jvacx.2018.100002 · DOI
  110. Sitthidet, 2011, Identification of Motifs of Burkholderia pseudomallei BimA Required for Intracellular Motility, Actin Binding, and Actin Polymerization, J. Bacteriol., 193, 1901, 10.1128/JB.01455-10 · DOI
  111. Kespichayawattana, 2000, Burkholderia pseudomallei Induces Cell Fusion and Actin-Associated Membrane Protrusion: A Possible Mechanism for Cell-to-Cell Spreading, Infect. Immun., 68, 5377, 10.1128/IAI.68.9.5377-5384.2000 · DOI
  112. Sitthidet, 2008, Prevalence and Sequence Diversity of a Factor Required for Actin-Based Motility in Natural Populations of Burkholderia Species, J. Clin. Microbiol., 46, 2418, 10.1128/JCM.00368-08 · DOI
  113. Mukhopadhyay, 2011, Molecular Characterization of Clinical Burkholderia pseudomallei Isolates from India, Am. J. Trop. Med. Hyg., 85, 121, 10.4269/ajtmh.2011.11-0166 · DOI
  114. Corea, E.M., de Silva, A.D., and Thevanesam, V. (2018). Melioidosis in Sri Lanka. Trop. Med. Infect. Dis., 3. · DOI
  115. Morris, 2017, Increased Neurotropic Threat from Burkholderia pseudomallei Strains with a B. mallei–like Variation in the bimA Motility Gene, Australia, Emerg. Infect. Dis., 23, 740, 10.3201/eid2305.151417 · DOI
  116. Sarovich, D.S., Price, E.P., Webb, J.R., Ward, L.M., Voutsinos, M.Y., Tuanyok, A., Mayo, M., Kaestli, M., and Currie, B.J. (2014). Variable Virulence Factors in Burkholderia pseudomallei (Melioidosis) Associated with Human Disease. PLoS ONE, 9. · DOI
  117. Gora, H., Hasan, T., Smith, S., Wilson, I., Mayo, M., Woerle, C., Webb, J.R., Currie, B.J., Hanson, J., and Meumann, E.M. (2022). Melioidosis of the Central Nervous System: Impact of the bimABm Allele on Patient Presentation and Outcome. Clin. Infect. Dis., ciac111. · DOI
  118. Campos, 2013, Functional Characterization of Burkholderia pseudomallei Trimeric Autotransporters, Infect. Immun., 81, 2788, 10.1128/IAI.00526-13 · DOI
  119. Adler, N.R.L., Stevens, M.P., Dean, R.E., Saint, R.J., Pankhania, D., Prior, J.L., Atkins, T.P., Kessler, B., Nithichanon, A., and Lertmemongkolchai, G. (2015). Systematic Mutagenesis of Genes Encoding Predicted Autotransported Proteins of Burkholderia pseudomallei Identifies Factors Mediating Virulence in Mice, Net Intracellular Replication and a Novel Protein Conferring Serum Resistance. PLoS ONE, 10. · DOI
  120. Coulthurst, 2019, The Type VI secretion system: A versatile bacterial weapon, Microbiology, 165, 503, 10.1099/mic.0.000789 · DOI
  121. Singh, 2023, Bacterial type VI secretion system (T6SS): An evolved molecular weapon with diverse functionality, Biotechnol. Lett., 45, 309, 10.1007/s10529-023-03354-2 · DOI
  122. DeShazer, 2019, A novel contact-independent T6SS that maintains redox homeostasis via Zn2+ and Mn2+ acquisition is conserved in the Burkholderia pseudomallei complex, Microbiol. Res., 226, 48, 10.1016/j.micres.2019.05.007 · DOI
  123. Toesca, 2014, The Type VI Secretion System Spike Protein VgrG5 Mediates Membrane Fusion during Intercellular Spread by Pseudomallei Group Burkholderia Species, Infect. Immun., 82, 1436, 10.1128/IAI.01367-13 · DOI
  124. Schwarz, 2014, VgrG-5 Is a Burkholderia Type VI Secretion System-Exported Protein Required for Multinucleated Giant Cell Formation and Virulence, Infect. Immun., 82, 1445, 10.1128/IAI.01368-13 · DOI
  125. Kostow, N., and Welch, M.D. (2022). Plasma membrane protrusions mediate host cell–cell fusion induced by Burkholderia thailandensis. Mol. Biol. Cell, 33. · DOI
  126. Schell, 2007, Type VI secretion is a major virulence determinant in Burkholderia mallei, Mol. Microbiol., 64, 1466, 10.1111/j.1365-2958.2007.05734.x · DOI
  127. Zhang, 2023, Role of type VI secretion system protein TssJ-3 in virulence and intracellular survival of Burkholderia pseudomallei, Biochem. Biophys. Res. Common., 682, 397, 10.1016/j.bbrc.2023.09.091 · DOI
  128. Spiewak, H.L., Shastri, S., Zhang, L., Schwager, S., Eberl, L., Vergunst, A.C., and Thomas, M.S. (2019). Burkholderia cenocepacia utilizes a type VI secretion system for bacterial competition. Microbiologyopen, 8. · DOI
  129. Schwarz, S., West, T.E., Boyer, F., Chiang, W.C., Carl, M.A., Hood, R.D., Rohmer, L., Tolker-Nielsen, T., Skerrett, S.J., and Mougous, J.D. (2010). Burkholderia Type VI Secretion Systems Have Distinct Roles in Eukaryotic and Bacterial Cell Interactions. PLoS Pathog., 6. · DOI
  130. Burtnick, 2011, The Cluster 1 Type VI Secretion System Is a Major Virulence Determinant in Burkholderia pseudomallei, Infect. Immun., 79, 1512, 10.1128/IAI.01218-10 · DOI
  131. Shalom, 2007, In vivo expression technology identifies a type VI secretion system locus in Burkholderia pseudomallei that is induced upon invasion of macrophages, Microbiology, 153, 2689, 10.1099/mic.0.2007/006585-0 · DOI
  132. Burtnick, 2010, Burkholderia mallei Cluster 1 Type VI Secretion Mutants Exhibit Growth and Actin Polymerization Defects in RAW 264.7 Murine Macrophages, Infect. Immun., 78, 88, 10.1128/IAI.00985-09 · DOI
  133. Tran, 2022, Clinical Utility of Combined Whole-cell Antigen and Recombinant Hemolysis Co-Regulated Protein 1-Enzyme-linked Immunosorbent Assays Reveals Underdiagnosed Cases of Melioidosis in Vietnam, Am. J. Trop. Med. Hyg., 107, 585, 10.4269/ajtmh.21-1143 · DOI
  134. Wagner, G.E., Berner, A., Lipp, M., Kohler, C., Assig, K., Lichtenegger, S., Saqib, M., Müller, E., Trinh, T.T., and Gad, A.M. (2023). Protein Microarray-Guided Development of a Highly Sensitive and Specific Dipstick Assay for Glanders Serodiagnostics. J. Clin. Microbiol., 61. · DOI
  135. Sengyee, 2021, Melioidosis Patient Survival Correlates with Strong IFN-γ Secreting T Cell Responses Against Hcp1 and TssM, Front. Immunol., 12, 698303, 10.3389/fimmu.2021.698303 · DOI
  136. Biryukov, S.S., Cote, C.K., Klimko, C.P., Dankmeyer, J.L., Rill, N.O., Shoe, J.L., Hunter, M., Shamsuddin, Z., Velez, I., and Hedrick, Z.M. (2022). Evaluation of two different vaccine platforms for immunization against melioidosis and glanders. Front. Microbiol., 13. · DOI
  137. Zhu, 2022, Hcp1-loaded staphylococcal membrane vesicle vaccine protects against acute melioidosis, Front. Immunol., 13, 1089225, 10.3389/fimmu.2022.1089225 · DOI
  138. Brunet, 2014, Type VI secretion and bacteriophage tail tubes share a common assembly pathway, EMBO Rep., 15, 315, 10.1002/embr.201337936 · DOI
  139. Backmann, 2010, Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns, Nat. Rev. Immunol., 10, 787, 10.1038/nri2868 · DOI
  140. Kumar, 2015, Shape and size-dependent immune response to antigen-carrying nanoparticles, J. Control. Release, 220, 141, 10.1016/j.jconrel.2015.09.069 · DOI
  141. Baranov, 2020, Modulation of Immune Responses by Particle Size and Shape, Front. Immunol., 11, 607954
  142. Shanks, 2009, Burkholderia mallei tssM Encodes a Putative Deubiquitinase That Is Secreted and Expressed inside Infected RAW 264.7 Murine Macrophages, Infect. Immun., 77, 1636, 10.1128/IAI.01339-08 · DOI
  143. Tan, 2010, Suppression of Host Innate Immune Response by Burkholderia pseudomallei through the Virulence Factor TssM, J. Immunol., 184, 5160, 10.4049/jimmunol.0902663 · DOI
  144. Burtnick, 2014, Proteomic Analysis of the Burkholderia pseudomallei Type II Secretome Reveals Hydrolytic Enzymes, Novel Proteins, and the Deubiquitinase TssM, Infect. Immun., 82, 3214, 10.1128/IAI.01739-14 · DOI
  145. Jacobsen, 2020, Structure and function of minor pilins of type IV pili, Med. Microbiol. Immunol., 209, 301, 10.1007/s00430-019-00642-5 · DOI
  146. Boddey, 2005, A Type IV Pilin, PilA, Contributes to Adherence of Burkholderia pseudomallei and Virulence In Vivo, Infect. Immun., 73, 1260, 10.1128/IAI.73.2.1260-1264.2005 · DOI
  147. Sangdee, 2011, Heterologously type IV pilus expressed proteins of Burkholderia pseudomallei is immunogenic but fails to elicit protective immunity in mice, Southeast Asian J. Trop. Med. Public Health, 42, 1190
  148. Wu, R., Stephenson, R., Gichaba, A., and Noinaj, N. (2020). The Big BAM Theory: An Open and Closed Case?. Biochim. Biophys. Acta Biomembr., 1862. · DOI
  149. Rayes, 2021, Lipoproteins in Gram-negative bacteria: New insights into their biogenesis, subcellular targeting and functional roles, Curr. Opin. Microbiol., 61, 25, 10.1016/j.mib.2021.02.003 · DOI
  150. Chatorvedi, 2017, Transmembrane β-barrels: Evolution, folding and energetics, Biochim. Biophys. Acta Biomembr., 1859, 2467, 10.1016/j.bbamem.2017.09.020 · DOI
  151. Ni, 2015, The Expression, Purification, and Structure Determination of BamA from E. coli, Methods Mol. Biol., 1329, 169, 10.1007/978-1-4939-2871-2_13 · DOI
  152. Mouhib, 2021, Influence of Detergent and Lipid Composition on Reconstituted Membrane Proteins for Structural Studies, ACS Omega, 6, 24377, 10.1021/acsomega.1c02542 · DOI
  153. Doerner, 2017, Extreme Dynamics in the BamA β-Barrel Seam, Biochemistry, 56, 3142, 10.1021/acs.biochem.7b00281 · DOI
  154. Iadanza, M.G., Schiffrin, B., White, P., Watson, M.A., Horne, J.E., Higgins, A.J., Calabrese, A.N., Brockwell, D.J., Tuma, R., and Kalli, A.C. (2020). Distortion of the bilayer and dynamics of the BAM complex in lipid nanodiscs. Commun. Biol., 3. · DOI
  155. Su, 2008, A genome level survey of Burkholderia pseudomallei immunome expressed during human infection, Microbes Infect., 10, 1335, 10.1016/j.micinf.2008.07.034 · DOI
  156. Johnson, 2008, NCBI BLAST: A better web interface, Nucleic Acids Res., 36, W5, 10.1093/nar/gkn201 · DOI
  157. Xu, Q., Guo, M., and Yu, F. (2023). β-Barrel Assembly Machinery (BAM) Complex as Novel Antibacterial Drug Target. Molecules, 28. · DOI
  158. Malinverni, 2006, YfiO stabilizes the YaeT complex and is essential for outer membrane protein assembly in Escherichia coli, Mol. Microbiol., 61, 151, 10.1111/j.1365-2958.2006.05211.x · DOI
  159. Singh, 2017, Immunoprotective potential of BamA, the outer membrane protein assembly factor, against MDR Acinetobacter baumannii, Sci. Rep., 7, 12411, 10.1038/s41598-017-12789-3 · DOI
  160. Conde, 2021, Cross-reactivity and immunotherapeutic potential of BamA recombinant protein from Acinetobacter baumannii, Microbes Infect., 23, 104801, 10.1016/j.micinf.2021.104801 · DOI
  161. Guan, 2016, In silico analysis and recombinant expression of BamA protein as a universal vaccine against Escherichia coli in mice, Appl. Microbiol. Biotechnol., 100, 5089, 10.1007/s00253-016-7467-y · DOI
  162. Storek, 2018, Monoclonal antibody targeting the β-barrel assembly machine of Escherichia coli is bactericidal, Proc. Natl. Acad. Sci. USA, 115, 3692, 10.1073/pnas.1800043115 · DOI
  163. Vij, 2018, A targeted boost-and-sort immunization strategy using Escherichia coli BamA identifies rare growth inhibitory antibodies, Sci. Rep., 8, 7136, 10.1038/s41598-018-25609-z · DOI
  164. Meng, 2023, UCSF ChimeraX: Tools for structure building and analysis, Protein Sci., 32, e4792, 10.1002/pro.4792 · DOI
  165. Hallgren, J., Tsirigos, K.D., Pedersen, M.D., Armenteros, J.J.A., Marcatili, P., Nielsen, H., Krogh, A., and Winther, O. (2023). DeepTMHMM predicts alpha and beta transmembrane proteins using deep neural networks. bioRxiv. · DOI
  166. McClean, 2016, Linocin and OmpW Are Involved in Attachment of the Cystic Fibrosis-Associated Pathogen Burkholderia cepacia Complex to Lung Epithelial Cells and Protect Mice against Infection, Infect. Immun., 84, 1424, 10.1128/IAI.01248-15 · DOI
  167. Casey, 2016, Identification of an OmpW homologue in Burkholderia pseudomallei, a protective vaccine antigen against melioidosis, Vaccine, 34, 2616, 10.1016/j.vaccine.2016.03.088 · DOI
  168. Bossi, 2021, BpOmpW Antigen Stimulates the Necessary Protective T-Cell Responses Against Melioidosis, Front. Immunol., 12, 767359, 10.3389/fimmu.2021.767359 · DOI
  169. Siritapetawee, 2004, Expression and refolding of Omp38 from Burkholderia pseudomallei and Burkholderia thailandensis, and its function as a diffusion porin, Biochem. J., 384, 609, 10.1042/BJ20041102 · DOI
  170. Kiekens, 2018, The Small RNA ncS35 Regulates Growth in Burkholderia cenocepacia J2315, mSphere, 3, e00579-17, 10.1128/mSphere.00579-17 · DOI
  171. Sass, 2023, The Small RNA NcS25 Regulates Biological Amine-Transporting Outer Membrane Porin BCAL3473 in Burkholderia cenocepacia, mSphere, 8, e00083-23, 10.1128/msphere.00083-23 · DOI
  172. Podnecky, N.L., Rhodes, K.A., and Schweizer, H.P. (2015). Efflux pump-mediated drug resistance in Burkholderia. Front. Microbiol., 6. · DOI
  173. Bachert, B.A., Choi, S.J., Snyder, A.K., Rio, R.V.M., Durney, B.C., Holland, L.A., Amemiya, K., Welkos, S.L., Bozue, J.A., and Cote, C.K. (2015). A Unique Set of the Burkholderia Collagen-Like Proteins Provides Insight into Pathogenesis, Genome Evolution and Niche Adaptation, and Infection Detection. PLoS ONE, 10. · DOI
  174. Grund, M.E., Choi, S.J., McNitt, D.H., Barbier, M., Hu, G., LaSala, P.R., Cote, C.K., Berisio, R., and Lukomski, S. (2020). Burkholderia collagen-like protein 8, Bucl8, is a unique outer membrane component of a putative tetrapartite efflux pump in Burkholderia pseudomallei and Burkholderia mallei. PLoS ONE, 15. · DOI
  175. Grund, M.E., Kramarska, E., Choi, S.J., McNitt, D.H., Klimko, C.P., Rill, N.O., Dankmeyer, J.L., Shoe, J.L., Hunter, M., and Fetterer, D.P. (2021). Predictive and Experimental Immunogenicity of Burkholderia Collagen-like Protein 8-Derived Antigens. Vaccines, 9. · DOI
  176. Grund, 2023, Intranasal immunization with a Bucl8-based vaccine ameliorates bacterial burden and pathological inflammation, and promotes an IgG2a/b dominant response in an outbred mouse model of Burkholderia infection, Front. Immunol., 14, 1177650, 10.3389/fimmu.2023.1177650 · DOI
  177. Manning, 1980, Outer membrane of Escherichia coli: Properties of the F sex factor traT protein which is involved in surface exclusion, J. Bacteriol., 142, 285, 10.1128/jb.142.1.285-294.1980 · DOI
  178. Perumal, 1984, The product of the F sex factor traT surface exclusion gene is a lipoprotein, J. Biol. Chem., 259, 5357, 10.1016/S0021-9258(18)91011-2 · DOI
  179. Chamberlain, 1989, Major integral membrane protein immunogens of Treponema pallidum are proteolipids, Infect. Immun., 57, 2872, 10.1128/iai.57.9.2872-2877.1989 · DOI
  180. Brandt, 1990, Immunogenic integral membrane proteins of Borrelia burgdorferi are lipoproteins, Infect. Immun., 58, 983, 10.1128/iai.58.4.983-991.1990 · DOI
  181. Wilson, 2016, Surface Exposed Lipoproteins: An Emerging Secretion Phenomenon in Gram-negative Bacteria, Trends Microbiol., 24, 198, 10.1016/j.tim.2015.11.006 · DOI
  182. Schell, 2011, Outer membrane proteome of Burkholderia pseudomallei and Burkholderia mallei from diverse growth conditions, J. Proteome Res., 10, 2417, 10.1021/pr1012398 · DOI
  183. Sousa, S.A., Seixas, A.M.M., Mandal, M., Rodríguez-Ortega, M.J., and Leitão, J.H. (2020). Characterization of the Burkholderia cenocepacia J2315 Surface-Exposed Immunoproteome. Vaccines, 8. · DOI
  184. Teufel, 2022, SignalP 6.0 predicts all five types of signal peptides using protein language models, Nat. Biotechnol., 40, 1023, 10.1038/s41587-021-01156-3 · DOI
  185. Hara, Y., Mohamed, R., and Nathan, S. (2009). Immunogenic Burkholderia pseudomallei Outer Membrane Proteins as Potential Candidate Vaccine Targets. PLoS ONE, 4. · DOI
  186. Champion, 2016, Immunisation with proteins expressed during chronic murine melioidosis provides enhanced protection against disease, Vaccine, 34, 1665, 10.1016/j.vaccine.2016.02.038 · DOI
  187. Dyke, 2020, The Peptidoglycan-associated lipoprotein Pal contributes to the virulence of Burkholderia mallei and provides protection against lethal aerosol challenge, Virulence, 11, 1024, 10.1080/21505594.2020.1804275 · DOI
  188. Michel, 2015, Dual orientation of the outer membrane lipoprotein Pal in Escherichia coli, Microbiology, 161, 1251, 10.1099/mic.0.000084 · DOI
  189. Michel, 2013, Dual Orientation of the Outer Membrane Lipoprotein P6 of Nontypeable Haemophilus influenzae, J. Bacteriol., 195, 3252, 10.1128/JB.00185-13 · DOI
  190. Shinoy, M., Dennehy, R., Coleman, L., Carberry, S., Schaffer, K., Callaghan, M., Doyle, S., and McClean, S. (2013). Immunoproteomic Analysis of Proteins Expressed by Two Related Pathogens, Burkholderia multivorans and Burkholderia cenocepacia, during Human Infection. PLoS ONE, 8. · DOI
  191. Makidon, 2010, Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine, Med. Microbiol. Immunol., 199, 81, 10.1007/s00430-009-0137-2 · DOI
  192. Dennehy, R., Romano, M., Ruggiero, A., Mohamed, Y.F., Dignam, S.L., Troncoso, C.M., Callaghan, M., Valvano, M.A., Berisio, R., and McClean, S. (2016). The Burkholderia cenocepacia peptidoglycan-associated lipoprotein is involved in epithelial cell attachment and elicitation of inflammation. Cell. Microbiol., 19. · DOI
  193. Peri, 2016, Evolving serodiagnostics by rationally designed peptide arrays: The Burkholderia paradigm in Cystic Fibrosis, Sci. Rep., 6, 32873, 10.1038/srep32873 · DOI
  194. Varga, 2012, Distinct human antibody response to the biological warfare agent Burkholderia mallei, Virulence, 3, 510, 10.4161/viru.22056 · DOI
  195. Nithichanon, 2018, Immune Control of Burkholderia pseudomallei––Common, High-Frequency T-Cell Responses to a Broad Repertoire of Immunoprevalent Epitopes, Front. Immunol., 9, 484, 10.3389/fimmu.2018.00484 · DOI
  196. Seixas, A.M.M., Sousa, S.A., Feliciano, J.R., Gomes, S.C., Ferreira, M.R., Moreira, L.M., and Leitão, J.H. (2021). A Polyclonal Antibody Raised against the Burkholderia cenocepacia OmpA-like Protein BCAL2645 Impairs the Bacterium Adhesion and Invasion of Human Epithelial Cells In Vitro. Biomedicines, 9. · DOI
  197. Davidson, 2008, Structure, Function, and Evolution of Bacterial ATP-Binding Cassette Systems, Microbiol. Mol. Biol. Rev., 72, 317, 10.1128/MMBR.00031-07 · DOI
  198. Rees, 2009, ABC transporters: The power to change, Nat. Rev. Mol. Cell Biol., 10, 218, 10.1038/nrm2646 · DOI
  199. Garmory, 2004, ATP-Binding Cassette Transporters Are Targets for the Development of Antibacterial Vaccines and Therapies, Infect. Immun., 72, 6757, 10.1128/IAI.72.12.6757-6763.2004 · DOI
  200. Harland, D.N., Dassa, E., Titball, R.W., Brown, K.A., and Atkins, H.S. (2007). ATP-binding cassette systems in Burkholderia pseudomallei and Burkholderia mallei. BMC Genom., 8. · DOI

200 of 248 shown

Metadata

Authors
Badten, A. J., & Torres, A. G.
Affiliations
The University of Texas Medical Branch at Galveston (US)
Corresponding author
Torres, Alfredo G.
ORCID
Torres, Alfredo G.
Venue
Vaccines
Publisher
MDPI AG
Published
2024-03-15
Volume
12
Issue
3
Pages
313
ISSN
2076-393X (ISSN-L)
DOI
10.3390/vaccines12030313
PMC
PMC10975474
OpenAlex
W4392857477
Cited by
8
References
1
Citations by year
2026: 1 · 2025: 5 · 2024: 2
FWCI
0.53
Type
journal article
Language
en
Open access
Licence
Locations
  • Vaccines (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (T32AI060549)
  • UTMB Health (T32AI060549)
Topics
  • Health Sciences › Medicine › Epidemiology › Burkholderia infections and melioidosis
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
  • Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
Keywords
Burkholderia cepacia complex, subunit vaccine, glycoconjugate vaccines, cross-protection, melioidosis, glanders, Burkholderia mallei, sequence conservation, cystic fibrosis, opportunistic infections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review